A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.

The level of protection achieved by the standard two doses of COVID-19 mRNA vaccines in patients receiving maintenance hemodialysis (MHD) remains unclear. To study this we used the French Renal Epidemiology and Information Network (REIN) Registry to compare the incidence and severity of 1474 cases of COVID-19 diagnosed in patients receiving MHD after none, one or two doses of vaccine. Vaccination significantly reduce COVID-19 incidence and severity but 11% of patients infected after two doses still died.

Source: Kidney International - November 29, 2021 Category: Urology & Nephrology Authors: Maxime Espi, Xavier Charmetant, Thomas Barba, Cyrille Mathieu, Caroline Pelletier, Laetitia Koppe, Elodie Chalencon, Emilie Kalbacher, Virginie Mathias, Anne Ovize, Emmanuelle Cart-Tanneur, Christine Bouz, Laurence Pellegrina, Emmanuel Morelon, Laurent Ju Tags: clinical investigation Source Type: research